Arcus Biosciences, Inc. · NYSE:RCUS

Arcus Biosciences — Investor Presentation (February 2025)

33 slides from Arcus Biosciences's investor presentation, Feb 25, 2025

  1. Slide 1: Combining to Cure

    COMBINING TO CURE ® Arcus is at the forefront of designing combination therapies, with best-in-class potential, in the relentless pursuit of cures for cancer. CORPORATE PRESENTATION February 25, 2025

  2. Slide 2: Forward-Looking Statements/Safe Harbor

    Forward-Looking Statements/Safe Harbor Forward Looking Statements Safe Harbor: This presentation contains forward-looking statements about Arcus Biosciences, Inc. (“we,” “Arcus” or the “Company”) made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All

  3. Slide 3: Broad Portfolio of Late-Stage Programs, Fueled by a Highly Productive R&D Engine

    Arcus Has Created a Broad Portfolio of Late-Stage Programs, Fueled by a Highly Productive R&D Engine CASDATIFAN: POTENTIAL BEST-IN-CLASS WORLD-CLASS HIF-2α INHIBITOR DRUG DISCOVERY Small molecules focused on Validated mechanism and Phase 3 initiation expected oncology and I&I compelling market oppor

  4. Slide 4: Three Late-Stage Programs Targeting Substantial Market Opportunities and Unmet Medical Need

    Three Late-Stage Programs Targeting Substantial Market Opportunities and Unmet Medical Need Designed to improve upon the current standard of care PATIENTS MARKET PHASE 3 (MAJOR POTENTIAL COMMERICAL TRIAL NAME INDICATION MARKETS1,2) (MAJOR MARKETS2) RIGHTS CAS Post-IO ccRCC 19K ~$2B HIF-2α small Arcu

  5. Slide 5: 2024 Validating Data Readouts Across the Program Portfolio

    2024 Validating Data Readouts Across the Program Portfolio CONFERENCE STUDY PRODUCT DATA READOUT Improvement across all efficacy measures cas evaluated relative to belzutifan data in (HIF-2α) LITESPARK-005 dom (+zim) 0.64 OS hazard ratio for dom/zim vs. zim in 1L (TIGIT+PD-1) PD-L1 high NSCLC dom (+

  6. Slide 6: Multiple Data Milestones in 2025 Expected to Enhance Clarity

    Multiple Data Milestones in 2025 Expected to Enhance Clarity on Multi-Billion $ Opportunities for Casdatifan and Domvanalimab TIMING STUDY PRODUCT EVENT  Updated data from 50mg BID, 50mg QD (ORR, PFS) Early 2025 Casdatifan  Initial data from 100mg QD tablet (ORR) mono cohort • Safety and initial e

  7. Slide 7: Casdatifan (HIF-2α) in ccRCC

    Casdatifan (HIF-2α) in ccRCC 7 © Arcus Biosciences 2024

  8. Slide 8: ARC-20 Results Presented at ASCO GU Support Casdatifan Best-in-Class Profile

    ARC-20 Results Presented at ASCO GU Support Casdatifan Having a Potential Best-in-Class Profile for ccRCC Across all three expansion cohorts 100mg QD tablet1 (approximately 90 patients) (Selected Phase 3 dose and formulation)  Lower primary progressive disease (PD) rate – approximately half the rat

  9. Slide 9: ARC-20 is a Phase 1 Dose-Escalation and Dose-Expansion Study of Casdatifan

    ARC-20 is a Phase 1 Dose-Escalation and Dose-Expansion Study of Casdatifan DOSE ESCALATION DOSE EXPANSION Patients with advanced solid tumors N = ~30 per cohort Casdatifan monotherapy 2L+ ccRCC Casdatifan mono 150mg QD 2L+ ccRCC 200mg QD Casdatifan mono Post-IO ccRCC 50mg BID capsule Casdatifan 100m

  10. Slide 10: Key Efficacy Measures Compare Favorably to Benchmark Studies

    Key Efficacy Measures All Compare Very Favorably to Contemporary Benchmark Studies Despite Shorter Follow-up Casdatifan 50mg BID Casdatifan 50mg QD Casdatifan 100mg QD Efficacy-Evaluable Population1,2 (n = 32) (n = 28) (n = 27) 25% (8) 32% (9)** 33% (9) Confirmed ORR (n) [95% CI] [11.5, 43.4] [15.9,

  11. Slide 11: Kaplan-Meier Estimates of Progression Free Survival

    50mg BID and 50mg QD Cohorts Show Substantially Improved PFS Relative to that of LITESPARK-005 50mg BID Cohort (n=32) 50mg QD Cohort (n=28) 1.0 1.0 Belz LS-005 Belz LS-005 mPFS (Ph 3): mPFS (Ph 3): 0.9 0.9 5.6 months 5.6 months 0.8 0.8 Kaplan-Meier Estimates of Kaplan-Meier Estimates of Progression

  12. Slide 12: ARC-20 Data Support Casdatifan's Potential Best-in-Class Profile

    ARC-20 Data Support Casdatifan’s Potential Best-in-Class Profile Across All Cohorts and Outcome Measures Lower Primary PD Higher ORR* Higher DCR Improved mPFS 35% 34% 33% 100% 32%* 9.7 86% 85% 10.0 30% 81% 80% 25% 25% 22% 61% 5.6 19% 60% 20% 5.0 15% 14% 15% 40% 10% 20% 0.0 5% mPFS (months) mPFS not

  13. Slide 13: Vision for Cas as the HIF-2α Inhibitor of Choice; Earlier Lines of Treatment

    Our Vision is for Every ccRCC Patient to Receive a HIF-2α Inhibitor and for Cas to be the HIF-2α Inhibitor of Choice EST. 2024 PATIENT DOT SETTING COMBINATION POPULATION (MONTHS) ARCUS APPROACH Neoadjuvant cas + zimberelimab Investigator-sponsored trial to 3-4 ccRCC (anti-PD-1) 57k initiate in March

  14. Slide 14: First Phase 3 Study for Cas Has a Simple Design

    First Phase 3 Study for Cas Has a Simple Design that Utilizes the Preferred SOC in Post-IO ccRCC PATIENT POPULATION: • Unresectable, locally advanced or metastatic N~700 PRIMARY ccRCC 100MG CASDATIFAN + ENDPOINT: • Measurable disease per CABOZANTINIB • PFS RECIST 1.1 KEY SECONDARY R • Have had prior

  15. Slide 15: Cas Will Be Offered as a Single 100mg QD Tablet

    Cas Will Be Offered as a Single 100mg QD Tablet LITESPARK-011 (Merck) Cas 100mg Cabo 20-60mg Belz 120mg Lenva 20mg (1 x 100mg) (1 x Xmg) (3 x 40mg) (2 x 10mg) • Cas tablet strengths will minimize pill burden while enabling dose reductions AE: adverse event; cas: casdatifan; cabo: cabozantinib; belz:

  16. Slide 16: Domvanalimab in Non-Small Cell Lung Cancer and Upper GI Cancers

    Domvanalimab in Non-Small Cell Lung Cancer and Upper GI Cancers 16 © Arcus Biosciences 2024

  17. Slide 17: Dom is the Most Clinically Advanced Fc-Silent Anti-TIGIT Antibody

    Dom is the Most Clinically Advanced Fc-Silent Anti-TIGIT Antibody in Development TIGIT inhibition turns an immuno-suppressive First-to-Market potential in Upper GI & “brake” into an accelerator of adaptive immunity the only Fc-silent anti-TIGIT in Ph3 NSCLC 1 2 Dom blocks TIGIT, an inhibitory TIGIT

  18. Slide 18: Dom/Zim/Chemo: Unprecedented mPFS in 1L Gastric Cancer

    Dom/Zim/Chemo: Unprecedented mPFS in 1L Gastric Cancer EDGE-Gastric: TAP ≥ 5% (n=16); EDGE-Gastric Data Exceeded TAP < 5% (n=24) Benchmark Data CHECK KEY 13.8 months EDGE- RATIONALE MATE- NOTE- 100 GASTRIC -3053 KM Estimate of Progression Free median PFS 6491 8592 TAP ≥5% 75 ITT 12.9m 7.7m 6.9m 6.9m

  19. Slide 19: Phase 3 Study was Fully Enrolled in June 2024

    Phase 3 Study was Fully Enrolled in June 2024 Dom + zim is positioned to be the first anti-TIGIT combination approved STAR-221 is evaluating the same regimen in the same setting as EDGE-Gastric 1L locally N=1,046 DUAL PRIMARY advanced ENDPOINTS: domvanalimab + zimberelimab + • OS ITT unresectable or

  20. Slide 20: ARC-7 and ARC-10 Consistent Improvement for Dom + Zim in 1L PD-L1 High NSCLC

    ARC-7 and ARC-10 Demonstrated Consistent Improvement for Dom + Zim in 1L PD-L1 High NSCLC 1L PD-L1 High NSCLC 1L PD-L1 High NSCLC dom + zim vs. zim vs. etruma + dom + zim (n=150) dom + zim vs. zim or chemo (n=95) Dom + Zim Zim Dom + Zim Zim Median PFS 9.3 months 5.4 months Median OS NR 24.4 months [

  21. Slide 21: Phase 3 Evaluating Dom + Zim + Chemo vs. Pembro + Chemo in 1L NSCLC

    Phase 3 Evaluating Dom + Zim + Chemo vs. Pembro + Chemo in 1L NSCLC (All PD-L1 Subgroups) • Uses standard of care, pembrolizumab, in the comparator arm ELIGIBILITY CRITERIA: ARM A ENDPOINTS: • Metastatic NSCLC without dom + zim + platinum doublet PRIMARY actionable mutations (ARM A vs B) • No prior

  22. Slide 22: Phase 3 Evaluating Dom + Durva in Unresectable Stage III NSCLC

    Phase 3 Evaluating Dom + Durva vs Placebo + Durva in Unresectable, Stage III NSCLC • Combines domvanalimab (dom) with durvalumab (durva) standard-of-care in Stage III NSCLC • Potential to be first anti-TIGIT combination in this curative intent setting PATIENT POPULATION: ARM A (N=430) PRIMARY ENDPOI

  23. Slide 23: CD73-Adenosine Axis Programs

    CD73-Adenosine Axis Programs 23 © Arcus Biosciences 2024

  24. Slide 24: Three Datasets in Six Months Demonstrate Benefits of Adenosine Blockade with Chemotherapy

    Three Datasets in Six Months Demonstrate the Potential Benefits of Combining Adenosine Blockade with Chemotherapy 3L Colorectal Cancer 1L Metastatic PDAC 1L Metastatic PDAC etruma + zim + FOLFOX/bev vs. rego (n=112) quemli ± zim + G/nP (n=122) etruma + atezo + G/nP (n=35) 100 100 100 EZFB etruma + a

  25. Slide 25: Quemliclustat: A Small Molecule CD73 Inhibitor with Key Attributes

    Quemliclustat (quemli): A Small Molecule CD73 Inhibitor with Several Key Attributes QUEMLICLUSTAT • Highly potent small molecule Potential advantages over • Target coverage achieved at doses CD73 antibodies1 as low as 25 mg every two weeks • Extremely long (4+ days) half-life, enabling Q2W dosing by

  26. Slide 26: Phase 3 Study of Quemli + Chemo in 1L Metastatic PDAC

    Phase 3 Study of Quemli + Chemo in 1L Metastatic PDAC 1L mPDAC Stratification • ECOG 0/1 Arm A: Quemli 100mg Q2W + • Liver metastases GnP PRIMARY ENDPOINT: • Confirmed PDAC untreated • *Region • OS in metastatic setting • Metastatic disease diagnosed 2:1 within 6 weeks prior to KEY SECONDARY screeni

  27. Slide 27: Etrumadenant Represents a Potentially Best-in-Class Adenosine Receptor Antagonist

    Etrumadenant Represents a Potentially Best-in-Class Adenosine Receptor Antagonist ETRUMADENANT Etrumadenant has an ideal profile • Highly potent small molecule that inhibits both the A2a and A2b receptors  Retains potency in physiologically • Excellent penetration of tumor tissue relevant condition

  28. Slide 28: AXL Program

    AXL Program 28 © Arcus Biosciences 2024

  29. Slide 29: AB801 is a Potent, Selective AXL Inhibitor

    AB801 is a Potent, Selective AXL Inhibitor AXL signals via Ligand-dependent and AB801 is a highly potent Ligand-independent mechanisms and selective AXL inhibitor Assay AB801 AXL Ki 0.024 nM MERTK EGFR TYRO3 VEGFR HER2 Fold selectivity over hMERTK/ hTYRO3 860x / 1400x BIOCHEMICAL (enzyme Ki over AXL

  30. Slide 30: AB801 is Potentially the Most Potent & Selective AXL Inhibitor in Clinical Development

    AB801 is Potentially the Most Potent & Selective AXL Inhibitor in Clinical Development THERAPEUTIC HYPOTHESIS: Inhibiting AXL will overcome resistance against chemotherapy and immunotherapy in human tumors • AB801 was designed to potently and selectively inhibit AXL signaling in tumors, resulting in

  31. Slide 31: Phase 1 Dose-Finding Study in Patients with Advanced Solid Tumors

    Phase 1 Dose-Finding Study in Patients with Advanced Solid Tumors PRE-SCREENING / SCREENING DOSE ESCALATION STAGE EXPANSION STAGE DOSE ESCALATION PRIMARY ENDPOINT • Safety / DLT AB801 SECONDARY ENDPOINT • PK • ORR AB801 EXPLORATORY ENDPOINTS Advanced Solid Cohort 1: NSCLC • Biomarkers / PD Tumors AB

  32. Slide 32: Arcus Biosciences – Combining to Cure

    RCUS BIOSCIENCES COMBINING TO CURE”

  33. Slide 33: Our Partnerships Enable Cost-Efficiency and Greatly Expand Our Opportunities

    Our Partnerships Enable Cost-Efficiency and Greatly Expand Our Opportunities COST-SHARING R&D Phase 1/1b: cas + volru • Arcus retains co-promotion • Taiho has development / • Both parties retain rights and profit share in commercial rights in Japan economics on their the U.S. and rest of Asia (ex-Ch

Arcus Biosciences — Investor Presentation (February 2025) on 6ix